INTRODUCTION
The importance of non-prothrombin plasma and serum constituents in the physiological conversion of prothrombin to thrombin has been recognized only recently. A hemorrhagic disorder, called "parahemophilia" (Owren's disease), is associated with an elevated prothrombin time attributable to deficiency of a plasma component termed "Factor V" (1, 2) . Inadequacy of plasma Ac-globulin, required for rapid evolution of thrombin, has been described by Sykes and associates (3) in experimentally induced liver poisoning, and Alexander and Goldstein have reported on Labile Factor (Quick) deficiency in severe hepatic disease in man (4) . Although conclusive evidence is lacking, most investigators agree that Factor V, Acglobulin, and Labile Factor are identical. Subnormal concentrations result in retarded prothrombin conversion (elevated one-stage prothrombin time), in poor yield of thrombin by the two-stage prothrombin method, and in hemorrhagic phenomena despite the fact that the prothrombin level may actually be normal.
The clinical and laboratory investigation of a unique case herein reported provides substantial evidence that an additional constituent besides that (or those) described above is involved in prothrombin conversion, and that its lack may underlie a hemorrhagic diathesis, hitherto unrecognized, which simulates hypoprothrombinemia. Deficiency of Ac-globulin, Labile Factor, or Factor V were excluded as the basis for the clotting abnormality.
The evidence warrants the conclusion that the defect consisted in derangement of the early activation of prothrombin due to congenital inadequacy of the precursor of the serum prothrombin conversion IAided by grants from the Commonwealth Fund and The United States Public Health Service. accelerator (spca) described in earlier reports (5) (6) (7) (8) .
CASE REPORT 2 R (No. 309157), a four year old white girl of Scotch, Irish, French and Dutch extraction, was admitted to the Children's Medical Center, Boston, on June 13, 1950 , with bloody stools and hematemesis of three days' and six hours' duration, respectively. The family history was contributory only in the fact that the mother stated that she and her brother bruised easily and that the maternal grandfather died of intestinal bleeding following trauma.
The patient, an only child, was noted to have prolonged bleeding from the umbilical cord at birth. On the eighth and tenth days, she passed gross blood per rectum, which continued until the age of five weeks when she was first admitted to the Children's Medical Center. At that time her blood count, platelet count, and bleeding and clotting times were normal. The prcthrombin was not determined. Although the barium enema was negative, an exploratory laparotomy was performed because cf continued melena. No cause for the intestinal bleeding could be found, the abdominal organs appeared normal, and the appendix was removed. No undue hemorrhage was encountered, and convalescence was uneventful except for mild melena which continued for several months.
The patient's intervening history was perfectly normal save for easy bruising and occasional spontaneous epistaxis. Three weeks prior to her second admission she began to experience urinary urgency, frequency, and burning, unassociated with other symptoms. Five days prior to admission, she fell and sustained some bruises. The next day she passed four tarry stools, pallor was noted, and the patient became progressively listless. On the day of admission she began to bleed from the nose, vomited "coffee-ground" material on three occasions, and complained of crampy abdominal pain.
Physical examination revealed a fairly well developed, thin, very pale, quiet child who appearead acutely ill. T After considerable improvement, with no recurrence of hematemesis or melena, the patient was discharged on the eighth day. She was seen8 again four months later at which time her clotting defect was found relatively unchanged; her prothrombin time was 62 seconds, her coagulation time (Lee-White, 370 C), 17 minutes (normal: 4-12 minutes.). The investigation of the coagulation defect is recorded below.
METHOD
Prothrombin was determined by both the one-and twostage methods. In the former, two procedures were employed: the prothrombin time was observed on whole oxalated plasma (1 part 0.1 M sodium oxalate to 9 parts venous blood), and on whole-plasma diluted with pooled oxalated normal plasma rendered prothrombin free by adsorption with BaSO4 (hereafter referred to as BaSO, plasma), according to techniques previously described 8 At the Yamins Research Laboratory. (9) . In some experiments, the patient's plasma was mixed with normal plasma unadsorbed with BaSO4. Commercial rabbit brain thromboplastin (Difco) was used throughout except where indicated otherwise.
In the two-stage procedure, also, two methods were used: the orthodox technique (10) , and the modification of Ware and Seegers (11) in which optimal amounts of Ac-globulin are provided by bovine BaCO, adsorbed serum (1 to 150 dilution). Discrepancies between the results reflect inadequacy of Ac-globulin in the system not containing the bovine serum. Beef lung provided the source of thromboplastin, and Armour Fraction I provided the fibrinogen.
Plasma Labile Factor (L.F.) was measured by the ability of the plasma to rectify the retarded prothrombin conversion of aged normal oxalated pooled plasma in which this clotting component had deteriorated (12, 13) .
The serum prothrombin conversion accelerator (spca) was determined by a method previously described (5) . Serum devoid of spca was prepared by adsorption with BaSO4 (100 mgm. per ml.) for ten minutes at room temperature.
Preparations of prothrombin were obtained from plasma by adsorption with BaSO, and elution with 5% solutions of sodium citrate in physiological saline, as described in earlier reports (14, 8) . Purified spca was similarly prepared from serum according to published methods (8) .
RESULTS
One-and two-stage plasma prothrombin values:
The prothrombin time of the patient's whole plasma was repeatedly found elevated to approximately 70 seconds consistent with a prothrombic activity of about 3%o of normal (Table I) . This was not referable to prothrombin deficiency, how- This hypothesis became untenable when it was found that the prothrombin time was still far above normal when bovine lung thromboplastin was substituted for rabbit brain (Table III) . Similar results were also obtained with human brain thromboplastin (acetone dehydrated). Curiously, whereas human thromboplastin was more effective than bovine thromboplastin on normal plasma, it was less effective on the patient's plasma. The explanation for this is obscure. Exclusion of Ac-globulin deficiency: The question arose as to whether the retarded thrombin evolution was due to inadequacy of any of the known prothrombin-conversion factors. Deficiency of Ac-globulin was easily excluded: twostage plasma prothrombin determinations by the orthodox procedure, in which supplements of Acglobulin are not provided, gave values almost as good as those obtained with added Ac-globulin (Table I, Figure 1 ). The slightly lower values are not unusual in our experience with hundreds of measurements on normal plasma, and are in accordance with the finding of Murphy and Seegers that normally the concentration of Acglobulin in man is critically low (15) . Also noteworthy is the normal activation rate of the prothrombin within the interval observed ( Figure 1 ). This was found repeatedly.
Exclusion of labile factor deficiency: L. F. concentration was also relatively normal. The restorative activity of the patient's plasma, whole or treated with BaSO4, on the retarded prothrombin conversion of aged plasma, was approximately 70%o of normal ( Figure 2 ), a level not infrequently observed in patients with active or recent bleeding. This concentration is certainly sufficient to assure a normal prothrombin time if other clottitig constituents are normal (16, 12) . That the coagu- Prothrombin activation performed on a 1 to 40 dilution of test plasma with saline or with a 1 to 150 bovine serum-saline mixture.
lation defect could not be attributed to L. F. deficiency is established by the observation that diluting the patient's plasma with BaSO, normal plasma, which contains a full complement of L. F. (16, 17) failed to rectify the abnormality (Table   II) . Also, diluting normal plasma with the patient's BaSO4 plasma gave essentially the same prothrombin times as were obtained on normal plasma similarly diluted with normal BaSO4 plasma (Table II) . It is, therefore, concluded that the clotting defect was not related to deficiency of Ac-globulin, of L. F., or of any entity contained in BaSO4 adsorbed normal plasma. Exclusion of Factor V deficiency: Although it is likely that Ac-globulin and L. F. are identical with Factor V, inadequacy of the latter had to be ruled out by methods employed by Owren in his case of parahemophilia (1, 2) . In his subject, the elevated prothrombin time could be rectified by admixture of deprothrombinated Seitz-filtered normal plasma with the pathological plasma. Accordingly, 35 ml. of normal oxalated plasma were passed through a Seitz filter. The first 5 ml. were discarded, and the remainder was refiltered through the same pad. The 9, respectively, failed to clot in six minutes. On the basis of these and other observations (see below), parahemophilia was excluded.
Possibility of qualitative defect in patient's prothrombin Conceivably the patient's prothrombin might have been inherently defective, and thus in its early activation only slowly susceptible to the action of thromboplastin and calcium. This might escape detection in the two-stage method where, although thrombin evolution takes place, it is not discernible until after a longer interval (minutes) of interaction between the coagulation components than in the one-stage system (seconds). To test this possibility, the patient's prothrombin was separated and purified. The prothrombin, which was thus obtained in full yield, behaved like that in the whole plasma: it was normal when measured in the two-stage system but when it was added to BaSO4 normal plasma its one-stage conversion was still retarded (Table IV) . The possibility still remained, therefore, that the prothrombin molecule itself was abnormal. Clearly, this question can be conclusively answered only by testing the prothrombin in an ideal diluent consisting of hypoprothrombinemic plasma assuredly containing all the accessory prothrombin factors.
Patient's prothrombin consumption: Although two-stage prothrombin conversion was normal, it was of interest to see whether the retarded onestage thrombin formation was associated with decreased prothrombin consumption during the course of spontaneous coagulation. Accordingly, the following experiments were performed: venous blood, drawn with a siliconized syringe and needle, was allowed to clot in clean non-siliconized dry test tubes. At specific intervals after the blood was withdrawn, oxalate was added, the mixture was stirred with a glass rod, and the tubes were centrifuged. Residual prothrombin in the sera was determined by the modified two-stage method. Contrary to what was expected, prothrombin consumption was found perfectly normal ( Figure 3 ). This indicates that if prothrombin conversion was retarded, it was so only in an early phase of the clotting process, perhaps within that interval represented by the one-stage prothrombin time where initial thrombin formation is detected. Apparently, as "clotting" proceeded, the velocity of thrombin elaboration increased and soon became normal. This interpretation is consistent with the normal plasma prothrombin values obtained by the twostage method, where normal activation and maximal yield of thrombin was evident within a few minutes after thromboplastin and calcium were added to the system (Figure 1 ). Under the conditions of the two-stage procedure, a disturbance in the earliest phase of prothrombin activation could escape detection. lation to the amount or velocity of prothrombin conversion (6, 7) . This substance, distinct from Ac-globulin, is considered by us to be the "autocatalytic" accelerator of thrombin formation (8) .
Arising from an as yet unidentified precursor in plasma, it apparently potentiates the action of thromboplastin (8) . Both spca and its progenitor are adsorbable by BaSO, (5, 7, 8, 14) .
In view of the role of spca in prothrombin conversion, it was of interest to study the elaboration of spca during coagulation of the patient's blood. The spca activity of her serum was generally abnormally low despite normal jrothrombin consumption (Table V) Table V) .
Obtained 60 minutes after blood withdrawn. Contained 6 units prothrombin per ml. Same preparation as described in Table IV . Obtained from patient's plasma used in this experiment. Solution containing 1 mgm. protein, 38 units spca, per ml.
prothrombic activity, as measured by the orthodox one-stage method, decreases during storage because of deterioration of L. F. (12, 14, 18) . When, however, determinations are made by the modified procedure in which the aged plasma is diluted with fresh BaSO4 plasma, the stored plasma shows increased prothrombic activity. Such "hyperactivity" also develops in aging prothrombin fractions obtained by BaSO, adsorption, and elution with citrate (14) . This is attributable to evolution of a prothrombin conversion accelerator, which because of its resemblance to spca with regard to activity, stability and adsorbability by BaSO4, has been identified with spca. This phenomenon was not demonstrable in the pathological plasma: during storage of the oxalated plasma in glass at refrigerator temperature for 25 days, no significant change in prothrombic activity was observed.
Effect of spca on the clotting defect: All of these findings suggested a derangement in the spca mechanism. Experiments were therefore performed to ascertain whether normal serum rich in spca could affect prothrombin conversion in the patient's plasma. When normal serum was mixed with the pathological plasma, the prothrombin time was markedly decreased (Table VI) . In contrast, the patient's serum was relatively inert on both her own as well as on normal plasma. Normal serum also induced more rapid thrombin evolution from a prothrombin preparation derived from the abnormal plasma, and the same results were obtained when purified spca fractions were substituted for normal serum. Furthermore, re- Clearly, the administration of normal plasma should have some beneficial effect since mixtures of normal with the pathological plasma exhibit at least the full prothrombic activity of the normal plasma (Table II) . The question arises whether more activity is demonstrable than can be accounted for by the normal plasma alone, i.e., whether normal plasma accelerates thrombin evolution from the patient's prothrombin. It would appear that normal plasma was relatively inert in this regard (Table II) mgm. BaSO, (C. P.-Baker) at 4-5o C for approximately ten minutes. The adsorbed plasma had a prothrombin time of 70 seconds. The prothrombin times of normal-pathological plasma mixtures were also shorter than those of normal plasma similarly diluted with this hypoprothrombinemic plasma (Table VII) . Here, too, the differences were evident only at high dilutions, i.e., in mixtures with prothrombin times exceeding 30 seconds.
Additional experiments were performed: 1 part of normal plasma was mixed with 1 part of pathological plasma. The ensuing mixture was then diluted with various amounts of prothrombin-free BaSO, normal plasma, and the prothrombin times were compared with those simultaneously obtained on normal plasma diluted with the BaSO, normal plasma. In this way, the same diluent was provided to both the normal plasma and the normalpathological combination. Again, prothrombin conversion seemed faster in mixtures containing both normal and pathological plasma ( Figure 5) , particularly in the range where the prothrombin time exceeded 28 seconds. Mixtures of pathological plasma alone with the BaSO, normal plasma gave markedly elevated prothrombin times, which became progressively greater as dilution with the BaSO, nornmal plasma was increased. Curve with circles represents observations on normal plus pathological plasma, diluted in BaSO4 normal plasma. Ten% There can be little doubt, however, that to a certain extent normal plasma can truly rectify the retarded prothrombin conversion of the abnormal plasma. It is, however, far less effective than serum (Table VII) . Furthermore, the clot-promoting effect of serum, and also of spca preparations, was observable in all ranges of prothrombin time, whereas the nomal plasma seemed effective only in mixtures with prothrombin times in excess of approximately 30 seconds. The explanation of this is obscure. Either the correcting factor in normal plasma is present in critical amounts, insufficient to handle substantial amounts of the additional prothrombin provided by the patient's plasma, or a certain interval (about 30 seconds) is required after the addition of thromboplastin and calcium for the corrective effect of normal plasma to supervene. Certainly the prothrombin method is sufficiently sensitive to have permitted detection of clot-promoting effect also in ranges where the prothrombin times of mixtures were between 20 and 30 seconds. Thus, in the presence of an amount of normal plasma which would give a prothrombin time of less than 30 seconds, the corrective effect of the factor in normal plasma may not be evident if 30 seconds or more is required for its conversion to the component active in correction of the clotting defect.
Regardless of whether this interpretation is correct, the clot-promoting effect of normal plasma provides strong evidence against the hypothesis that the patient's prothrombin was inherently defective. It is more reasonable to conclude that the abnormality lay in deficiency of a coagulation factor present in normal plasma, but absent in BaSO4 plasma.
Clot-promoting effect of dicumarol plasma:
Consistent with this conclusion is the observation that hypoprothrombinemic dicumarol plasma also could induce thrombin evolution in the patient's plasma (Table VIII) . This finding, furthermore, reflects a striking difference between dicumarol plasma and normal plasma deprothrombinated by BaSO4. Moreover, BaSO4 adsorption of the dicumarol plasma decreases its effect. This lends further support to the concept that the clotting factor present in normal plasma and deficient in the patient is adsorbable by BaSO4.
DISCUSSION
Recent recognition of the importance of nonprothrombin factors in the conversion of prothrombin has permitted more precise delineation of the coagulation defect in certain patients who formerly would have been erroneously grouped in one category, namely, hypoprothrombinemia. Exhaustive study of these rare cases has led, at least in one instance (1) , to the discovery of hitherto unknown clotting components.
The observations contained in this report indicate the existence of another prothrombin-conversion factor besides those already reported. Deficiency in this entity (or its deranged function) results in early retardation of thrombin evolution, a defect which is associated with hemorrhagic phenomena despite essentially normal concentrations of prothrombin, Ac-globulin, L. F., and Factor V.
The existence of another prothrombin-conversion plasma component was postulated by Quick on the basis of observations on two brothers with abnormal bleeding and elevated prothrombin times (19) . This moiety, originally termed "prothrombin A," is not reduced by dicumarol in contrast to "prothrombin B," which is probably identical with the purified prothrombin of Seegers, Loomis and Vandenbelt (20) . Prothrombin A is said to be adsorbed by alumina and calcium phosphate together with Prothrombin B, in contradistinction to L. F. (19) . The subject has been further complicated by the most recent change in terminology by Quick and Stefanini who now consider the total "prothrombin complex" to comprise three components: prothrombin "A," prothrombin "pre-A" and L. F. (18) .
Alexander and associates, also, have presented evidence of a prothrombin conversion factor in plasma, distinct from L. F. or Ac-globulin. This entity is probably the inert precursor of spca to which it becomes converted during coagulation (14, 8) . Like prothrombin, it is adsorbed by BaSO4, and thus is probably identical with Quick's prothrombin A (earlier terminology) and perhaps with Milstone's prothrombokinase, which also is removed by BaSO, (21) . Additional evidence for this factor was obtained by Landwehr and associates on a subject with congenital hypoprothrombinemia (22) . When normal plasma was diluted with the prothrombinopenic plasma, the ensuing mixture exhibited considerably faster prothrombin conversion than a mixture of normal plasma with normal plasma deprothrombinated by BaSO4 Furthermore, treatment of the prothrombinopenic plasma with this adsorbing agent obviated the accelerating effect, yielding a plasma indistinguishable from normal BaSO4 plasma. Evidently, this patient's plasma contained a prothrombin-conversion substance adsorbable by BaSO4 and not present in BaSO, normal plasma.
From the data of the present report it is concluded that our patient's clotting disturbance consisted in deficiency of this entity, the precursor of spca. We have seen that the pathological serum contained little spca after coagulation had run its course, and that normal serum or spca fractions rectified the retarded prothrombin activation. Furthermore, removal of spca rendered the serum inert.
Also in harmony with this interpretation are some of the other observations. Whereas normal or dicumarol plasma can partially correct the clotting defect, adsorption of the plasmas with BaSO, renders them relatively inert. This indicates that BaSO4 removes the accessory factor in question. It also explains why the patient's plasma, assumed to be deficient in this entity, acted almost the same as BaSO4 normal plasma as a diluent for normal plasma in the one-stage test. Furthermore, prothrombin preparations obtained from the abnormal plasma would be expected, as was found, to show the same clotting defect when mixed with BaSO4 normal plasma.
Certain deductions may be drawn regarding the role of this clotting factor in prothrombin conversion. By the two-stage method, the rate of thrombin evolution as well as the final yield of thrombin from the patient's prothrombin appeared normal. Also, prothrombin consumption during spontaneous coagulation was unimpaired. Since under these conditions the prothrombin conversion process can be accurately followed except during the first few minutes after the addition or appearance of thromboplastin, it may be justifiably concluded that the clotting derangement lay in this phase of prothrombin activation, indeed, in the very interval represented by the elevated one-stage prothrombin time. It thus appears that the clotting factor, deficient in the pathological plasma, functions somehow in the early activation of prothrombin by thromboplastin plus calcium. Its similarity, in this regard also, to Milstone's prothrombokinase is striking (21) .
The discrepancy in "prothrombin" values obtained on this patient by the one-and two-stage procedures raises questions regarding the validity of these methods, and their clinical diagnostic value. Obviously, the clotting disturbance would have escaped detection had the two-stage system been used exclusively. On the other hand, it is equally clear that the one-stage test, even the modification using BaSO4 normal plasma as a diluent to assure adequate L. F., may fail to measure prothrombin specifically, since it is now apparent that BaSO, removes an important accessory substance. As has been emphasized elsewhere (9, 22, 23) , unless due consideration is given to all the prothrombin-conversion factors as well as to the concentrations of fibrinogen, antithrombin and anticoagulants, translation of an observed prothrombin time into a specific prothrombin value may be fraught with serious error. Nevertheless, this case demonstrates the distinct value of the one-stage method in disclosing certain clotting abnormalities centered around the conversion of prothrombin to thrombin.
The clot-promoting effect of serum and purified spca is of practical as well as theoretical interest. To reduce the prothrombin time from 70 to 22 seconds is tantamount to increasing plasma prothrombic activity from about 3%7 to 25% of normal, a level which is consistent with effective hemostasis if other hemostatic mechanisms are normal (9) . It has been shown that serum as well as purified spca can promote the coagulation of normal blood, hemophilic blood, thrombocytopenic blood, heparinized blood and blood exposed to siliconized surfaces (8) . The therapeutic possibilities of serum were explored with good results by Crockett and colleagues (24) in a case of "idiopathic hypoprothrombinemia." It is noteworthy that in their subject, plasma seemed equally effective, the beneficial results of each lasting for 24 hours or more in contrast to the relatively shortlived effect of serum in our case. These authors attributed the clot-promoting property of serum to Ac-globulin, probably not being aware of the fact that one to two hour old human serum is practically devoid of Acglobulin activity (15, 8) .
The normal prothrombin consumption in our case is worthy of additional comment. Since poor prothrombin utilization characteristically occurs in hemophilia, thrombocytopenia, thrombasthenia and certain and other hemorrhagic states associated with defective coagulation, the prothrombin consumption test promises to become important in distinguishing hemorrhagic conditions, related to clotting abnormalities, from other forms of pathological bleeding. That our patient's defect was associated with normal prothrombin consumption is, therefore, particularly noteworthy. Furthermore, it renders untenable our earlier concept that spca elaboration is related to the amount and/or velocity of prothrombin conversion (6, 7) . Also, it signifies the importance in normal hemostasis of the kinetics of thrombin elaboration rather than the overall amount of prothrombin converted.
The literature fails to reveal cases which completely simulate that presented in this report. Quick (19) described two brothers with elevated prothrombin times which he attributed to deficiency of "prothrombin A" (earlier terminology). It is of interest that these subjects also showed good prothrombin consumption. Unfortunately, they were not exhaustively studied by simultaneous one-and two-stage prothrombin determinations as well as by measurements of plasma Acglobulin and serum spca. The condition was called "pseudohypoprothrombinemia," a term which we consider more suitably applicable to a group of disorders including Ac-globulin deficiency (parahemophilia) and the derangement represented by our case. Since in our subject the condition was evident at birth, it is most probably congenital in origin.
